{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:17:26Z","timestamp":1787170646865,"version":"build-2736575974"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.lungcan.2021.03.021","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T04:54:26Z","timestamp":1617252866000},"page":"196-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Squamous cell carcinoma associated with acquired von Willebrand disease due to immune checkpoint inhibitor treatment"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-5878","authenticated-orcid":false,"given":"Toshiyuki","family":"Sumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2021.03.021_bib0005","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","article-title":"Immunotherapy in non-small cell lung cancer: facts and hopes","volume":"25","author":"Doroshow","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2021.03.021_bib0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2021.03.021_bib0015","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1055\/s-0037-1614018","article-title":"Subcommittee on von Willebrand factor. Acquired von Willebrand syndrome: data from an international registry","volume":"84","author":"Federici","year":"2000","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.lungcan.2021.03.021_bib0020","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1089\/cren.2018.0032","article-title":"Acquired von Willebrand disease secondary to clear cell renal cell carcinoma","volume":"4","author":"Odom","year":"2018","journal-title":"J. Endourol. Case Rep."},{"key":"10.1016\/j.lungcan.2021.03.021_bib0025","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-205248","article-title":"Acquired von Willebrand\u2019s disease associated with epithelial myoepithelial carcinoma of the parotid salivary gland","volume":"2014","author":"Chilvers","year":"2014","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.lungcan.2021.03.021_bib0030","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1365-2141.1992.tb04562.x","article-title":"Acquired type II von Willebrand\u2019s disease associated with adrenal cortical carcinoma","volume":"80","author":"Facon","year":"1992","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lungcan.2021.03.021_bib0035","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/annonc\/mdi171","article-title":"Hepatocellular carcinoma associated with acquired von Willebrand disease and extreme thrombocytosis","volume":"16","author":"Chen","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2021.03.021_bib0040","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2021.03.021_bib0045","first-page":"100049","article-title":"Acquired coagulopathy with immune checkpoint inhibitors \u2013 an under-recognized association between inflammation and coagulation","volume":"1","author":"Joseph","year":"2020","journal-title":"JTO Clin. Res. Rep."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221001288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221001288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:52:47Z","timestamp":1759236767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500221001288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":9,"alternative-id":["S0169500221001288"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.03.021","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Squamous cell carcinoma associated with acquired von Willebrand disease due to immune checkpoint inhibitor treatment","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}